Orthogonal CRISPR/Cas system facilitated dual-color fluorescence fiber-embedded optofluidic nano-biochip for parallel amplification-free on-site detection of bacterium and virus.

Publication date: Jun 12, 2025

Bacterial and viral co-infections significantly exacerbate morbidity and mortality. Rapid, sensitive, and parallel detection of these pathogens remains a critical challenge. Here, an orthogonal CRISPR/Cas system facilitated dual-color fluorescence fiber-embedded optofluidic nano-biochip (CD-FOB) was fabricated. Leveraging the time-resolved effect, the CD-FOB achieved ultrasensitive parallel detection of Escherichia coli O157:H7 (E. coli O157:H7) and SARS-CoV-2 based on a multiple signal enhancement strategy, including the collateral cleavage activity of CRISPR/Cas, evanescent wave fluorescence enhancement, DNA-mediated signal amplification, and air-displacement fluorescence enhancement. Without the need for amplification, the CD-FOB system has a detection limit of 643 CFU/mL for E. coli O157:H7 and 3. 48 copies/μL for SARS-CoV-2 within 50 min analysis time. To enable rapid on-site detection, a lyophilized CRISPR/Cas assay was prepared using stabilized freeze-dried reagents for detecting E. coli O157:H7 and SARS-CoV-2 in actual samples, achieving recoveries ranging from 70. 5% to 200. 5%. The unique combination of technical simplicity, multiplexing capability, and operational robustness positions CD-FOB as a versatile solution for combating current and future pathogen threats.

Concepts Keywords
50minanalysis Biosensing Techniques
Bacterium COVID-19
Cleavage CRISPR-Cas Systems
Exacerbate Escherichia coli O157
Viral Fluorescence
Humans
Lab-On-A-Chip Devices
Limit of Detection
Optical Fibers
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease IDO site
disease MESH co-infections
disease MESH morbidity
pathway REACTOME Signal amplification
drug DRUGBANK Medical air
disease IDO assay
disease IDO pathogen
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)